TY - JOUR T1 - Early and longitudinal microglial activation but not amyloid accumulation predict cognitive outcome in PS2APP mice JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.118.217703 SP - jnumed.118.217703 AU - Carola Focke AU - Tanja Blume AU - Benedikt Zott AU - Yuan Shi AU - Maximilian Deussing AU - Finn Peters AU - Claudio Schmidt AU - Gernot Kleinberger AU - Simon Lindner AU - Franz-Josef Gildehaus AU - Leonie Beyer AU - Barbara von Ungern-Sternberg AU - Peter Bartenstein AU - Laurence Ozmen AU - Karlheinz Baumann AU - Mario M Dorostkar AU - Christian Haass AU - Helmuth Adelsberger AU - Jochen Herms AU - Axel Rominger AU - Matthias Brendel Y1 - 2018/10/01 UR - http://jnm.snmjournals.org/content/early/2018/10/11/jnumed.118.217703.abstract N2 - Neuroinflammation may have beneficial or detrimental net effects on the cognitive outcome of Alzheimer’s disease patients (AD). 18kDa translocator protein (TSPO) imaging by positron-emission-tomography (PET) enables longitudinal monitoring of microglial activation in vivo. We compiled serial PET measures of TSPO and amyloid with terminal cognitive assessment (water maze) in an AD transgenic mouse model (PS2APP) from eight to 13 months of age, followed by immunohistochemical analyses of microglia, amyloid and synaptic density. Better cognitive outcome and higher synaptic density in PS2APP mice was predicted by higher TSPO expression at eight months. The progression of TSPO activation to 13 months also showed a moderate association with spared cognition, but amyloidosis did not correlate with the cognitive outcome, regardless of the timepoint. This first PET investigation with longitudinal TSPO- and amyloid-PET together with terminal cognitive testing in an AD mouse model indicates that continuing microglial response seems to impart preserved cognitive performance. ER -